title: Pilot study of a combination of S-1 and paclitaxel for patients with peritoneal metastasis from gastric cancer.
abstract: BACKGROUND
  This pilot study was carried out to evaluate the efficacy of chemotherapy for patients with peritoneal dissemination from gastric cancer or positive lavage cytology diagnosed by staging laparoscopy.
  
  
  METHODS
  Sixteen patients were enrolled. Paclitaxel was administered at 120 mg/m(2) on day 1 and S-1 was administered orally at 80 mg/m(2) for 14 consecutive days, followed by a 1-week rest, as one course. After five courses of this therapy, the primary gastric tumors were evaluated and second-look laparoscopy was performed for patients showing partial response or stable disease with clinical benefit.
  
  
  RESULTS
  Partial response or stable disease with clinical benefit was confirmed in seven and five patients, respectively, and these patients underwent second-look laparoscopy. No viable cancer cells were detected on cytopathological investigation during second-look laparoscopy in 9 patients who underwent surgical treatment. The intent-to-treat response rate for gastric tumor was 44% and the rate of disappearance of peritoneal metastasis was 38% (6 cases) at surgery. The median survival time was 555 days. Leucopenia of grade 3 and neutropenia of grade 3 were recognized in two and three patients, respectively.
  
  
  CONCLUSIONS
  This chemotherapy regimen may be an acceptable option for patients with peritoneal dissemination. We plan to study this regimen further in gastric cancer patients with peritoneal dissemination.
authors.affiliation: Department of Surgery, Kansai Rosai Hospital, Amagasaki, Hyogo, 660-8511, Japan.
authors.forename: Shigeyuki
authors.initials: S
authors.lastname: Tamura
authors.forename: Hirofumi
authors.initials: H
authors.lastname: Miki
authors.forename: Kaoru
authors.initials: K
authors.lastname: Okada
authors.forename: Atsushi
authors.initials: A
authors.lastname: Takeno
authors.forename: Kumiko
authors.initials: K
authors.lastname: Uji
authors.forename: Atsuko
authors.initials: A
authors.lastname: Yoshida
authors.forename: Rei
authors.initials: R
authors.lastname: Suzuki
authors.forename: Shin
authors.initials: S
authors.lastname: Nakahira
authors.forename: Chiyomi
authors.initials: C
authors.lastname: Egawa
authors.forename: Ken
authors.initials: K
authors.lastname: Nakata
authors.forename: Shu
authors.initials: S
authors.lastname: Okamura
authors.forename: Keishi
authors.initials: K
authors.lastname: Sugimoto
authors.forename: Yuichi
authors.initials: Y
authors.lastname: Takatsuka
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D004338:Drug Combinations; D005260:Female; D006801:Humans; D010535:Laparoscopy / Q000379:methods; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010094:Oxonic Acid / Q000008:administration & dosage; D017239:Paclitaxel / Q000008:administration & dosage; D010534:Peritoneal Neoplasms / Q000188:drug therapy* / Q000556:secondary; D010865:Pilot Projects; D011446:Prospective Studies; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology; D015996:Survival Rate; D005641:Tegafur / Q000008:administration & dosage
chemical_list: D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D017239:Paclitaxel